Uncategorized

Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study

Published

on

Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer.

The biotech on Tuesday shared Phase 2

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version